Eugenics Medicare Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-10-2024
- Paid Up Capital ₹ 0.96 M
as on 23-10-2024
- Company Age 16 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.50 M
as on 23-10-2024
- Revenue %
(FY 2023)
- Profit -3.54%
(FY 2023)
- Ebitda 5.84%
(FY 2023)
- Net Worth -1.95%
(FY 2023)
- Total Assets -0.24%
(FY 2023)
About Eugenics Medicare
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.96 M.
The company currently has active open charges totaling ₹7.50 M.
Ranjeet Singh, Gurjeet Kaur, and Angad Singh serve as directors at the Company.
- CIN/LLPIN
U85120UP2008PTC034751
- Company No.
034751
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Mar 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Eugenics Medicare?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ranjeet Singh  | Managing Director | 04-Mar-2008 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Angad Singh | Director | 13-Sep-2024 | Current |
| Gurjeet Kaur | Director | 04-Mar-2008 | Current |
Financial Performance of Eugenics Medicare.
Eugenics Medicare Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 3.54% decrease in profit. The company's net worth dipped by a decrease of 1.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eugenics Medicare?
In 2023, Eugenics Medicare had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Eugenics Medi Sciences Private LimitedActive 18 years 8 monthsRanjeet Singh, Gurjeet Kaur and 1 more are mutual person
- Primewest Marketing Private LimitedActive 12 years 2 months
Ranjeet Singh, Gurjeet Kaur and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Oriental Bank Of Commerce Creation Date: 26 Mar 2010 | ₹7.50 M | Open |
How Many Employees Work at Eugenics Medicare?
Unlock and access historical data on people associated with Eugenics Medicare, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eugenics Medicare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eugenics Medicare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
